1. A national stakeholder roundtable
REPORTING ON:
RTMP Symposium
April 20th, 2017
What Canadians need to know
about their medications
A national stakeholder roundtable
Dr. Lise M. Bjerre, MD, PhD, CCFP
University of Ottawa,
Department of Family Medicine

2. Welcome!
From the NPF, Barry Thorsteinson attended on behalf of Herb John and participated in both the morning and afternoon sessions.
Dr. Lise M. Bjerre, MD, PhD
University of Ottawa, Department of Family Medicine

3. Welcome
These are the providers of medication information who presented about their products during the morning session of the day. UpToDate was also invited but declined to attend.
Dr. Lise M. Bjerre, MD, PhD
University of Ottawa, Department of Family Medicine

4. Acknowledgements Funded by: In-Kind Support from: RTMP Members
Stakeholder participants who funded their own participation
Bruyère Research Institute, for the venue and AV equipment
DSECT for enabling participation via webinar
RTMP Members
Staff Support
Cody Black
Katie Ablett
Please mention that the meeting was funded by Canadian Institutes of Health Research (CIHR).
Dr. Lise M. Bjerre, MD, PhD
University of Ottawa, Department of Family Medicine

5. Introducing the RTMP
Group of researchers in Ottawa whose work focuses on medication appropriateness and access
We are action-oriented - motivated to improve medication information and appropriateness in Canada
Our specific goals are:
To create opportunities for networking and developing collaborative projects;
To provide RTMP researchers with a common platform to present their work and share relevant knowledge and findings; and,
To work toward the production of resources for use by a broad audience
Topic areas addressed by the RTMP include:
Clinical:  Medication management
Population: Pharmacoepidemiology
Resource allocation:  Pharmacoeconomics
Health Systems: Pharmaceutical policy
Dr. Lise M. Bjerre, MD, PhD
University of Ottawa, Department of Family Medicine

6.
Dr. Lise M. Bjerre, MD, PhD
University of Ottawa, Department of Family Medicine

7. Background “The federal government has taken the
very narrow, constitutionalist stance that pharmaceutical policy is, for the most part, solely a provincial responsibility. It offers no financial assistance for provincial drug plans, nor has it passed laws that would
ensure policy makers, health professionals, and patients have critical information about the safety, efficacy, and even the availability of drugs on the Canadian market.
Health care professionals and patients are left with limited scientific information
about which drugs are best for their patients, and scarcely any independent
information sources.”
From the Foreword by Steve Morgan, PhD
(June 2014)
There are a number of researchers in Ottawa who are concerned about this issue, which is part of what motivated me to form the Rational Therapeutics and Medication Policy Research Group, or RTMP.
Dr. Lise M. Bjerre, MD, PhD
University of Ottawa, Department of Family Medicine

8. Structure of the Day: Morning
We have a great day planned and a very full agenda!
The morning session is open to the public while the afternoon will be by invitation only.
Revise this slide – use screen print
Dr. Lise M. Bjerre, MD, PhD
University of Ottawa, Department of Family Medicine

9. Report Preview Current Status
Comments received from contributors and incorporated
As of 09/18/2017 report being finalized before sending back to contributors for first round endorsement
Second round of endorsement to follow
Anticipated publication date November 2017

10. Recommendations KEY PRIORITY: NEEDS ASSESSMENT Answer the question:
The report presents a high-level work plan to address the roundtable’s key priority to move forward:
KEY PRIORITY:
NEEDS ASSESSMENT
Answer the question:
"How do we capitalize upon the existing resources we have, while moving towards a universally accessible Canadian medication reference?”

11. Our Recommendations
The report puts forward six high-level recommendations aimed at encouraging the federal government and its provincial and territorial counter-parts to support our call to action on these issues.
The recommendations are being held in confidence until the publication date.

12. How you can help Support communications activities Social media
Press contacts
Contacts with other key stakeholder organizations
NPF’s role?
Participation on Steering Committee
Patient engagement working group
Other ideas?
Funding opportunities
Support communications activities
Do you use social media personally?
Do you have any contacts in the press?
Are there any key stakeholder organizations who may wish to endorse or receive the report, and/or help promote it through their communications channels?
What role might the NPF want to play in helping move forward with the next steps articulated in the report?
Possibilities include participation on Steering Committee or patient engagement working group or both
Other ideas?
Can the NPF think of any funding opportunities or other resources that we could draw from to support future work?
Would the NPF be interested in participating in an initial planning meeting following the report’s publication?

13. Thank you!
Should you have any question, concerns or ideas to share, please contact Katie Ablett, Research Associate for Dr. Lise M. Bjerre, RTMP Research Group Lead, at